FDA Approves Dako Assays as CDx for Genentech's Breast Cancer Treatment
June 12, 2012
FDA Approves Dako Assays as CDx for Genentech's Breast Cancer Treatment
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
June 13, 2012 / Pharmacogenomics Reporter - Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug
May 1, 2012 / GenomeWeb Daily News - Dako, Genentech Partner on Companion Dx FDA Submission for Pertuzumab
December 9, 2011 / GenomeWeb Daily News - Dako, Genentech to Seek FDA OK on HER-2 Companion Tests for Herceptin in Gastric Cancer
August 12, 2009 / Pharmacogenomics Reporter - FDA Approves Dako Assays as CDx for Genentech Breast Cancer Drug
March 5, 2013 / GenomeWeb Daily News